Medien
Category: Press
Filtern nach
Dipharma SA recognized for the fourth consecutive year as one of the Best Places to Work in Switzerland
Chiasso, Switzerland – November 3, 2025 – Dipharma SA, a pharmaceutical company specializing in high-quality and improved medicines for rare diseases, is proud to announce that it has been recognized for the fourth time as one of the Best Places t...
Dipharma introduces an improved and protecting packaging solution for its Sapropterin products also in Far East countries
Chiasso, Switzerland, May 7, 2025 – Dipharma SA is pleased to announce the introduction of a new and innovative packaging solution to protect its Sapropterin products, designed specifically for far east countries. This solution aligns with the hig...
Dipharma SA recognized for the third time as one of the best places to work in Switzerland
Chiasso, Switzerland, December 4th, 2024 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the third time as one of the best places to work in Switzerland...
Dipharma SA bestätigt die Auszeichnung als einer der besten Arbeitgeber in der Schweiz
Chiasso, Switzerland, November 6th, 2023 | Dipharma SA, a pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized for the second time as one of the best places to work in Switzerlan...
Sapropterin Dihydrochlorid Pulver und Tabletten zur Herstellung einer Lösung zum Einnehmen
Chiasso, Switzerland and Reading, England, October 4th, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are delighted to announce the official launch of Sapropterin Dihydrochloride (“Sapropterin”) in the United Kingdom. Sapropterin Di...
Sapropterin Dipharma Ist jetzt in Europa und der Schweiz Verfügbar
Chiasso, Switzerland, July 3rd, 2023 – Dipharma SA (“Dipharma”) today announced that its product Sapropterin Dipharma is now available in main European Countries and in Switzerland. Sapropterin Dipharma is available in the form of soluble ta...
Dipharma und LogixX Pharma verkünden für das Generikum Sapropterin in Grossbritannien die Zulassung bekommen zu haben
Chiasso, Switzerland and Reading, England, June 27, 2023 – Dipharma SA (“Dipharma”) and LogixX Pharma (“LogixX”) are pleased to announce that the Medicines and Healthcare Products Regulatory Agency (“MHRA”) has granted Marketing Authorization for ...
Analog Pharma und Dipharma geben die genehmigung der us fda für einen abgekürzten antrag auf ein neues medikament (anda) für 20 mg generische nitisinon-kapseln (temperaturstabil) bekannt
Princeton, NJ and Chiasso, Switzerland, May 31 st , 2023 – Analog Pharma (member of Duchesnay Pharmaceutical Group, hereafter “Analog”) and Dipharma S.A. (“Dipharma”) are pleased to announce that their 20 mg nitisinone abbreviated new drug applica...
Dipharma SA wird als eines der besten Unternehmen der Schweiz für 2022 ausgezeichnet
Chiasso, September 15th, 2022 | Dipharma SA, a specialty pharmaceutical company specialized in high quality and improved medicines for rare diseases, has been recently recognized as one of the best places to work for in Switzerland. During the ass...
Analog Pharma und Dipharma geben bekannt, dass die US-amerikanische FDA einen abgekürzten antrag für ein neues arzneimittel (ANDA) für generische Nitisinon-kapseln (temperaturstabil) genehmigt hat
Rosemont, PA and Chiasso, Switzerland, June 21st, 2022 – Analog Pharma (“Analog”) and Dipharma S.A. (“Dipharma”) today announced that their nitisinone abbreviated new drug application (ANDA) has received final approval from the U.S. Food and Drug ...










English
Deutsch